Palisade Bio announced new Phase 1a/b data for PALI-2108, an oral PDE4 inhibitor designed for targeted delivery to the colon and ileum in ulcerative colitis patients. The data show sustained active metabolite levels above the IC90 threshold, supporting once-daily dosing and localized drug activity in the colon, which reduces inflammation and fibrosis pathways. Clinical improvements were observed in biomarkers and histology, with 100% clinical response and 40% remission in patients. These results support advancing PALI-2108 into Phase 2 trials for ulcerative colitis and Crohn's disease.
Fury Gold Mines has restarted exploration and drilling activities at its Eau Claire project in Northern Quebec following a temporary halt due to a nearby wildfire. All personnel have safely returned, and operations resumed after confirming safe condi...
YieldMax announced weekly distributions for three of its Performance & Distribution Target 25 ETFs: MSST, NVIT, and TEST. Each ETF targets a 25% annual income level, with distributions scheduled for July 29, 2026. These ETFs use a call writing strate...
Novo Nordisk has launched a share repurchase program to buy back B shares worth up to DKK 11.2 billion from May 2026 to February 2027, as part of a larger DKK 15 billion buyback plan starting February 2026. Since February, the company has repurchased...
Dimensional Fund Advisors Ltd. has disclosed ownership of 11,780,819 shares, representing a 1.26% stake in Prologis Inc as of July 24, 2026. This disclosure is made under the Takeover Code, indicating a significant investment position. The firm also ...
Man Group PLC has publicly disclosed holding a 1.63% interest in Senior Plc through cash-settled equity swaps as of July 24, 2026. This disclosure is made under Rule 8.3 of the UK Takeover Code, indicating a significant stake in the company. The posi...
